ArticleBritish journal of cancer2024

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.

Cath Eberlein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.